$ZURA Balance Sheet | Understand Stock

$ZURA

$3.56 +$0.20 (5.95%) Close

$ZURA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2026 As of Sep 30, 2026	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021
Assets
Current assets
Cash and cash equivalents
Due from related party
Prepaid expenses
Prepaid expenses and other current assets
Total current assets

Investments held in Trust Account
Deferred offering costs
Property and equipment, net
Other assets
Total assets

Liabilities and Shareholders’ Equity
Accounts payable
Accounts payable - related party
Accrued expenses
Due to related party
Note Payable - related party
Current liabilities
Accounts payable and accrued expenses
Note payable
Research and development license consideration liability
Total current liabilities
Deferred underwriting commissions
Derivative warrant liabilities

Private placement warrants
Total liabilities
Series A-1 convertible preferred shares, $0.001 par value, -0- and 13,510,415 shares authorized, issued and outstanding as of December 31, 2023 and 2022, respectively
Class A ordinary shares subject to possible redemption
Total series A-1 convertible preferred shares, $0.001 par value, -0- and 13,510,415 shares authorized, issued and outstanding as of December 31, 2023 and 2022, respectively
Redeemable noncontrolling interest
Shareholders’ Equity
Preferred shares, $0.0001 par value, 1,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued and outstanding as of September 30, 2025 and December 31, 2024
Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 96,306,411 and 73,680,710 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
Class A Ordinary shares
Class B Ordinary shares
Class A ordinary shares non-redeemable
Total class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 96,306,411 and 73,680,710 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

Additional paid-in capital
Accumulated deficit
Total Zura Bio Limited shareholders' equity
Noncontrolling interest
Total shareholders’ equity

Total liabilities and shareholders’ equity

Comments